Still Unclear Whether Kenilworth Will Ever File Anacetrapib With FDA For Approval...

The full (Oxford run) REVEAL study results are out, at a conference in Barcelona this morning. And they are a smallish success, in a fraught field -- but may also be the result of a non-novel action.

For almost as long as I've been writing this blog (as the prediction in the old graphic, at right would attest), I've been covering the twisted path various CETP programs have traversed, from Phase I to. . . today's news. Pfizer, Lilly, Roche and Merck all have seen varying disappointments -- over the last decade -- and some moderate successes. [Last Spring's backgrounder, on Lilly's travails.] So nnow we wai on Merck, o see if i files for approval.

I might say that a nine per cent improvement -- over a placebo (at this likely premium price; and accumulation in tissue profile) might not be enough, But we shall see. Onward. . . .

Be safe -- and do try to stay relatively dry -- in the Big Easy. . . Smile. . . .

नमस्ते